The drug candidate was one of three therapies the Swiss pharmaceutical company added to its pipeline through its $12 billion acquisition of Avidity Biosciences.
Source link
About The Author
Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial